Stiolto Respimat (tiotropium bromide and olodaterol) is a prescription drug used to treat chronic obstructive pulmonary disease (COPD). Stiolto Respimat can cause side effects that range from mild to ...
Respimat from Boehringer Ingelheim is now the first and only inhaler to be awarded the Ease of Use Commendation by the Arthritis Foundation. This award identifies products that make life easier for ...
Stiolto Respimat (tiotropium bromide/olodaterol) is an inhaled medication for the treatment of chronic obstructive pulmonary disease (COPD), bronchitis, and emphysema. However, it is not indicated for ...
BARCELONA, Spain — The risk for mortality in chronic obstructive pulmonary disease (COPD) patients being treated with tiotropium is the same whether the drug is delivered by the Respimat Soft Mist ...
Please provide your email address to receive an email when new articles are posted on . Stiolto Respimat helped improve quality of life and lung function in patients with COPD, according to study ...
FDA approves Boehringer Ingelheim’s Stiolto™* Respimat® as once-daily maintenance treatment for COPD
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved once-daily Stiolto™ Respimat ® (tiotropium bromide and olodaterol) Inhalation Spray. It has been approved ...
Striverdi Respimat (olodaterol) inhalation spray The FDA has approved Striverdi Respimat (olodaterol; Boehringer Ingelheim) inhalation spray for the treatment of patients with chronic obstructive ...
A post-hoc analysis from OTEMTO ® 1&2 indicates that Spiolto ® Respimat ® provides significant quality of life improvements over Spiriva ® Respimat ® (tiotropium) or placebo, right from the initial ...
INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced the publication of new data from the Phase IIIb OTEMTO ® 1&2 trials (NCT01964352 ...
Dortmund, Germany, 26 October 2012 – Successful treatment of respiratory diseases also depends on how much of the active substance enters the patient's lung. Boehringer Ingelheim's Respimat® Soft ...
Combivent Respimat Transition Almost Complete Transition of Combivent Respimat is nearly complete as Boehringer Ingelheim plans to cease distribution of Combivent MDI in May. Boehringer Ingelheim ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved Spiriva Respimat for the long-term, once-daily treatment of asthma in patients aged 12 years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results